

**SERVIER Methodological Note for Patient Organizations**

On disclosure of Transfer of Values (ToV) to Patient Organizations following Servier guidelines, as well as the interpretation of the EFPIA Code of Practice, EFPIA guidelines, and other industry codes in particular the IFPMA Note for Guidance on Patient and Patient Organization Interactions.

**1 Table of content**

2 **Introduction** ..... 2

3 **Purpose of the Methodological Note**..... 2

4 **Definitions**..... 2

5 **Description of funding category**..... 2

6 **Types of Transfers of Values being disclosed** ..... 3

7 **Disclosure Format of Transfer of Value to Patient Organizations** ..... 3

8 **Date of Transfers of Values** ..... 3

9 **Multi-year Agreements** ..... 3

10 **Consent Management** ..... 4

11 **Data Privacy** ..... 4

12 **Publication Currency**..... 4

13 **Date of Publication** ..... 4

14 **Reporting Year** ..... 4

15 **Disclosure Platform** ..... 4

16 **Disclosure Language** ..... 4

## 2 Introduction

Servier is committed to therapeutic progress to serve patient needs. We strongly believe that working with patients at all stages of the medicine's life cycle leads to better care and solutions to support them throughout their continuum of care.

Patients are taking more and more control of their own health, and patient organizations have expanded and evolved the active role of the patient community in the healthcare systems.

At Servier, we see this shift as a unique opportunity to work both with and for patients to develop solutions that better suit their needs. We involve them in our work, at every stage of the medicine life cycle. This dialogue is fundamental.

Their understanding of their illnesses and the medicines they take drive our activities (from R&D to post-launch) to better deliver patient outcomes.

Servier has developed guidelines following legal and regulatory requirements to ensure that the interactions with patient organizations meet high standards of integrity and transparency. Building greater transparency in the relationships between pharmaceutical companies and their partners aims to build a better understanding of the collaboration and recognition of its value to patient care.

## 3 Purpose of the Methodological Note

The present document serves as supporting documentation for the global patient organization ToV report and is intended to provide all methodological information relevant to the interpretation of the information disclosed by Servier as required by the EFPIA Code of Practice aligned with local transparency laws.

## 4 Definitions

The following definition of Patient Organization is provided by the EFPIA Code of Practice:

*“Non-for-profit legal person/entity (including the umbrella organization to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers and which business address, place of incorporation or primary place of operation is in Europe.”*

## 5 Description of funding category

Servier meets reporting obligations by publishing a global report for patient organization ToV which includes all the funding categories as per EFPIA code.

**Grants:** Funds, benefits-in-kind or services provided to an eligible organization to support a specific time-limited healthcare-related, medical, and/or scientific educational or research project or program aligned with Servier's corporate strategy without any tangible benefit in return (other than reputational).

**Donations:** support provided to advance the general mission or ongoing charitable efforts of a non-profit charitable organization, without any tangible benefit for Servier (other than reputational). Product supplies donations are excluded from this typology of donation.

**Sponsorship:** financial contribution in connection with a specific project or event in exchange for a tangible benefit for Servier.

**Contracted services:** Agreements to work on a specific project to which each party contributes and where each party has specific roles, obligations, and an interest in the project.

**Non-monetary support** Non-monetary support provided to the benefitting organization.

## 6 Types of Transfers of Values being disclosed

Transfers of Values disclosed by our Company consist in:

- **Direct ToV:** ToV, payments, made directly by Servier to the benefitting organization.
- **Indirect ToV:** ToV provided to the recipient through a third party. In this situation, our partners are required by contract to share with our Company all information relative to Transfers of Values to allow an appropriate preparation of the disclosure.
- **In-Kind:** non-monetary support provided to the benefitting organization.
- **Cross-border ToV:** ToV to an organization registered outside of the country where Servier subsidiary providing the funding is based. Where local law requires, such ToV is disclosed in the country where the organization has been formally registered. In addition, cross-border ToV made by Servier to organizations are included in the ToV report unless local law specifies otherwise.

ToV to an individual patient who does not represent or is not hired through a patient organization is not subject to disclosure except in some countries. Where local law requires, such ToV is disclosed by the Servier subsidiary at the country level.

## 7 Disclosure Format of Transfer of Value to Patient Organizations

For supports:

- The disclosure format includes a description of the nature of the support, the monetary value of financial support and of invoiced costs.
- For significant nonfinancial support that cannot be assigned a meaningful monetary value, the description describes the non-monetary benefit that the Patient Organization receives.

For contracted services: the total amount paid per Patient Organization over the Reporting Period is disclosed.

## 8 Date of Transfers of Values

As a standard rule, the date considered to prepare the disclosure corresponds to the date of the financial payment made to or for the benefit of the recipient.

## 9 Multi-year Agreements

Multi-year agreements refer to contracts with Patient Organizations that generate Transfers of Values beyond a period of twelve months.

This kind of agreements has no impact on the disclosure: only the date of each Transfer of Value, as isolated operation, is taken into consideration to prepare the reporting.

## 10 Consent Management

Consent publication is collected prior to the publication through a dedicated clause in the agreement. The consent expressed by the recipient is deemed valid for at least three years.

## 11 Data Privacy

Data privacy refers to the individual fundamental right to control the use of access to and disclosure of information that describes or identifies the individual ('personal information').

In some countries, this also applies to patient organizations. To fulfil the transparency disclosure requirements, it is necessary to collect, process, and disclose such data within Servier. In some countries, one consent may be required per interaction in order to comply with local data privacy principles.

In case no consent is given, or if our Company was unable to obtain a consent form duly filled by the recipient, the publication is made under the aggregate category.

## 12 Publication Currency

The currency used for the current publication is the local currency of the country that initiated the ToV.

Financial amounts indicated in the publication are expressed as VAT included.

## 13 Date of Publication

The date of publication is: 30/06/2024

## 14 Reporting Year

The publication relates to the previous calendar year (from 1<sup>st</sup> January to 31<sup>st</sup> December).

This information will remain available on the Internet for a period of 3 years after the date of the publication.

## 15 Disclosure Platform

The publication is provided through:

- Servier's publication page on <https://servier.com/en/transparency>

## 16 Disclosure Language

The publication is provided in English.